Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEPQ76)

Drug Name

CVN424 Drug Info

Synonyms

CVN424; XO01711URG; CVN-424; 2254706-21-1; UNII-XO01711URG; CHEMBL4778540; Ethanone, 1-(2-(4-(2,4-difluorophenoxy)-1-piperidinyl)-7,8-dihydro-3-(((3R)-tetrahydro-3-furanyl)amino)pyrido(3,4-b)pyrazin-6(5H)-yl)-; 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone; SCHEMBL20584477; GTPL11514; BDBM50582450; AKOS040759781; AT37427; HY-134661A; compound 6i [PMID: 33861086]; MS-28775; CS-0163733; Z3664677849

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 137359492
ChEBI ID: CHEMBL4778540
TTD Drug ID: DMEPQ76

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
G-protein coupled receptor 6 (GPR6)	TTSDWS5	GPR6_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04191577) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations. U.S.National Institutes of Health.
2	Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416.